The process begins by thawing the stored cells, cultivating them on increasing scales until reaching the ideal volume in the bioreactor. During this step, cells are optimized to produce and release the desired therapeutic proteins.
With the support of Bionovis’ quality control laboratory, each product is formulated, bottled and tested to ensure it meets the rigorous standards established by ANVISA and other global regulatory authorities.
It is important to highlight that in the process of developing a biopharmaceutical, non-clinical studies, both in vitro and in vivo, are essential to guarantee the safety and efficacy of the medicine [2]. Due to the intricate nature of protein molecules, biologic medicines cannot be copied identically, but can be replicated as equivalents, known as biosimilars.
In over more than a decade of operation, we have built partnerships with major global leaders in the pharmaceutical sector and public laboratories, such as: Bio-Manguinhos/FIOCRUZ, Fresenius Kabi, Johnson & Johnson Innovative Medicine, Merck, Samsung Bioepis and Sandoz. Through these partnerships, we receive the complete technology for the production of innovative biopharmaceuticals and biosimilars.
In addition, we have signed partnerships for commercialization in the private market, with INTAS, mAbxience and Samsung Bioepis.
Bionovis is a pioneer in the production and commercialization of biological and biosimilar medicines.
Our search for scientific innovations and highly complex medicines aims to build a healthier Brazil and world for everyone.
© 2025 Bionovis. Companhia Brasileira de Biotecnologia Farmacêutica.
